SLS Stock Overview
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
SELLAS Life Sciences Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.54 |
| 52 Week High | US$1.91 |
| 52 Week Low | US$0.50 |
| Beta | 2.37 |
| 1 Month Change | 43.93% |
| 3 Month Change | 197.30% |
| 1 Year Change | 10.79% |
| 3 Year Change | -81.27% |
| 5 Year Change | -96.91% |
| Change since IPO | -99.54% |
Recent News & Updates
Recent updates
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely
Jul 13
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely
Sep 20SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study
Aug 09We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully
Mar 08Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?
Nov 23Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Are In A Position To Invest In Growth
Jul 19SELLAS Life Sciences updates on at-the-market offering
Jun 02SELLAS Life Sciences jumps 43% after Reddit mentions
Feb 03Sellas' galinpepimut-S combo shows promising action in early-stage solid tumor studies
Dec 21Sellas Life Sciences strengthens balance sheet with addition of $30.5M
Dec 17Sellas Life Sciences prices $16.2M direct offering
Dec 14Nelipepimut-S data from breast cancer study fails to lift SELLAS Life Sciences
Dec 11SELLAS and 3D Medicines in exclusive license agreement for development and commercialization of GPS and GPS+ in Greater China
Dec 07SELLAS Life Sciences EPS misses by $0.26
Nov 13Shareholder Returns
| SLS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 13.2% | -2.5% | -3.2% |
| 1Y | 10.8% | -3.7% | 19.3% |
Return vs Industry: SLS exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: SLS underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| SLS volatility | |
|---|---|
| SLS Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SLS's share price has been volatile over the past 3 months.
Volatility Over Time: SLS's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 16 | Angelos Stergiou | www.sellaslifesciences.com |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials.
SELLAS Life Sciences Group, Inc. Fundamentals Summary
| SLS fundamental statistics | |
|---|---|
| Market cap | US$86.65m |
| Earnings (TTM) | -US$37.34m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.3x
P/E RatioIs SLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.34m |
| Earnings | -US$37.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SLS perform over the long term?
See historical performance and comparison